AbbVie is a Dividend King that's poised to return to solid growth. Bank of America has a strong record of dividend increases.

You know what I hate about the typical article about hottest dividend stocks to watch? You're excited about adding passive income to your portfolio, only to read about company after company that pa...

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of ...

AbbVie (ABBV) closed at $154.88 in the latest trading session, marking a +0.17% move from the prior day.

AbbVie needs to diversify its drug portfolio because of the loss of exclusive rights to Humira. The recent acquisition of ImmunoGen fills several needs and comes at an excellent time.

As the new year beckons, the pharmaceutical industry is poised for more developments, building on advances made in 2023. The industry harbors several companies leading the way in groundbreaking inn...

AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growt...

The S&P 500 Dividend Aristocrats Index contains 67 dividend growth stocks called the Dividend Aristocrats.

AbbVie is a top drugmaker that is putting its free cash flow to use lately with a couple of acquisitions. Abbott Labs has a broader, more diverse business that recently generated double-digit growth.

It's always a good time for investors to consider investing in blue-chip dividend stocks. In a sense, this class of equities is amongst the most established and stable investments possible.

Although a new year tends to bring optimism in the market, current vagaries warrant a discussion about bulletproof stocks to buy for 2024. To be fair, even the most influential voices in government...

Dividend stocks have always been and will be, among the most compelling choices for investors seeking stable and enduring returns.

Just for the fun of it and since we did not include it in our Outlook 2024, I decided to have a look at what experts are saying concerning mushrooms, cannabis, and hemp. After all, recreational and...

Colgate-Palmolive, Amgen, and others have solid records of increasing dividend payments.

Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.